Thus, therapeutic strategies that interfere with inflammatory markers, such as anti-tumor necrosis factor (TNF)-α treatment (e.g., infliximab and etanercept) and interleukin-24 therapy, are being investigated for the treatment of liver diseases [79,80]. The gene discussed is TNF; the disease is liver disorder.